However, based on the data obtained on other tumor models, we could speculate that drug combinations of ALDH-targeted agents with chemotherapies might enhance therapeutic response in PCa, including CSC populations responsible for the therapeutic tolerance, invasiveness of therapy-surviving cells, and relapse. The gene discussed is LDHA; the disease is neoplasm.